The estimated Net Worth of Partners L P/Ilbiotechnolog... is at least $33.5 million dollars as of 3 December 2013. Partners Ilbiotechnolog owns over 189,800 units of Rigel Pharmaceuticals stock worth over $16,237,325 and over the last 12 years Partners sold RIGL stock worth over $17,255,926.
Partners has made over 10 trades of the Rigel Pharmaceuticals stock since 2012, according to the Form 4 filled with the SEC. Most recently Partners bought 189,800 units of RIGL stock worth $950,898 on 3 December 2013.
The largest trade Partners's ever made was buying 1,289,354 units of Rigel Pharmaceuticals stock on 8 October 2013 worth over $6,885,150. On average, Partners trades about 328,564 units every 36 days since 2012. As of 3 December 2013 Partners still owns at least 1,251,914 units of Rigel Pharmaceuticals stock.
You can see the complete history of Partners Ilbiotechnolog stock trades at the bottom of the page.
Over the last 21 years, insiders at Rigel Pharmaceuticals have traded over $170,041,384 worth of Rigel Pharmaceuticals stock and bought 2,068,700 units worth $7,281,949 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Ansbert Gadicke et Partners L P/Ilbiotechnolog.... On average, Rigel Pharmaceuticals executives and independent directors trade stock every 46 days with the average trade being worth of $961,207. The most recent stock trade was executed by David A Santos on 2 February 2024, trading 14,519 units of RIGL stock currently worth $16,552.
rigel pharmaceuticals, inc., is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases.
Rigel Pharmaceuticals executives and other stock owners filed with the SEC include: